z-logo
open-access-imgOpen Access
Periostin interaction with discoidin domain receptor-1 (DDR1) promotes cartilage degeneration
Author(s) -
Tianzhen Han,
Paolo Mignatti,
Steven B. Abramson,
Mukundan Attur
Publication year - 2020
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0231501
Subject(s) - ddr1 , discoidin domain , periostin , cartilage , microbiology and biotechnology , proteoglycan , receptor tyrosine kinase , extracellular matrix , osteoarthritis , cancer research , chemistry , signal transduction , biology , pathology , medicine , anatomy , alternative medicine
Osteoarthritis (OA) is characterized by progressive loss of articular cartilage accompanied by the new bone formation and, often, a synovial proliferation that culminates in pain, loss of joint function, and disability. However, the cellular and molecular mechanisms of OA progression and the relative contributions of cartilage, bone, and synovium remain unclear. We recently found that the extracellular matrix (ECM) protein periostin (Postn, or osteoblast-specific factor, OSF-2) is expressed at high levels in human OA cartilage. Multiple groups have also reported elevated expression of Postn in several rodent models of OA. We have previously reported that in vitro Postn promotes collagen and proteoglycan degradation in human chondrocytes through AKT/β-catenin signaling and downstream activation of MMP-13 and ADAMTS4 expression. Here we show that Postn induces collagen and proteoglycan degradation in cartilage by signaling through discoidin domain receptor-1 (DDR1), a receptor tyrosine kinase. The genetic deficiency or pharmacological inhibition of DDR1 in mouse chondrocytes blocks Postn-induced MMP-13 expression. These data show that Postn is signaling though DDR1 is mechanistically involved in OA pathophysiology. Specific inhibitors of DDR1 may provide therapeutic opportunities to treat OA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here